Skip to main content
. 2021 Jan 5;12(5):1538–1547. doi: 10.7150/jca.52320

Figure 4.

Figure 4

Association of exosome-derived BTG-1 level with OS in patients with NSCLC. (A) Among all patients, the OS of patients with low plasma exosome-derived BTG-1 levels was shorter than that in patients with high plasma exosome-derived BTG-1 levels (P < 0.001); (B) OS was shorter in patients with low plasma exosome-derived BTG-1 levels than in patients with high plasma exosome-derived BTG-1 levels for those with TNM stage I (P = 0.023); (C) OS was shorter in patients with low plasma exosome-derived BTG-1 levels than in patients with high plasma exosome-derived BTG-1 levels for those with TNM stage I II (P = 0.021); (D) OS was shorter in patients with low plasma exosome-derived BTG-1 levels than in patients with high plasma exosome-derived BTG-1 levels for those with TNM stage III (P = 0.017).